The average price target is $2.00 with a high forecast of $2.00 and a low forecast of $2.00. Proteostasis Therapeutics EPS beats by $0.02, Proteostasis Therapeutics Reports Third Quarter 2020 Financial Results. The lighter blue line represents the stock's consensus price target. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. The company was formerly known as Proteoguard, Inc. and changed its name to Proteostasis Therapeutics, Inc. in September 2007. © American Consumer News, LLC dba MarketBeat® 2010-2021. Proteostasis Therapeutics Inc (PTI) stock is trading at $1.07 as of 2:16 PM on Monday, Nov 30, a decline of -$0.02, or -2.29% from the previous closing price of $1.09. Analysts have been projecting $3 as a low price target for the stock while placing it at a high target of $8. Fundamental company data provided by Zacks Investment Research. MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools. Nobody expects what they're predicting now... Proteostasis Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery and development of novel therapeutics to treat cystic fibrosis. For PTI, its debt to operating expenses ratio is greater than that reported by only 0.34% of US equities we're observing. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Only 4.80% of the stock of Proteostasis Therapeutics is held by insiders. This suggests that the stock has a possible downside of 73.7%. Learn everything you need to know about successful options trading with this three-part video course. Proteostasis Therapeutics employs 44 workers across the globe. Fundamental company data provided by Zacks Investment Research. Their average twelve-month price target is $4.67, predicting that the stock has a possible downside of 73.63%. Exicure started at outperform with $6 stock price target at BMO Capital Dec. 18, 2020 at 8:49 a.m. Current $1.11. You may vote once every thirty days. View which stocks are hot on social media with MarketBeat's trending stocks report. Shares of Adani Ports gained as much as 4.7% to Rs 474.9 apiece. The dark blue line represents the company's actual price. Average $4.67. Proteostasis Therapeutics does not have a long track record of dividend growth. The company can be reached via phone at 617-225-0096 or via email at [email protected]. Learn everything you need to know about successful options trading with this three-part video course. Identify stocks that meet your criteria using seven unique stock screeners. 4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. PTI stock research, analysis, profile, news, analyst ratings, key statistics, fundamentals, stock price, charts, earnings, guidance and peers. Wall Street is positive on Proteostasis Therapeutics Inc (PTI). Price target in 14 days: 1.928 USD. Proteostasis Therapeutics, Inc. was founded in 2006 and is headquartered in Boston, Massachusetts. The company earns $-59,130,000.00 in net income (profit) each year or ($1.16) on an earnings per share basis. View which stocks are hot on social media with MarketBeat's trending stocks report. The average price target is $8.666, which means analysts expect the stock to increase by 229.51% over the next twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Get daily stock ideas top-performing Wall Street analysts. Do Not Sell My Information. All times are ET. Learn more. Price/Sales: Latest closing price divided by the last 12 months of revenue/sales per share. After Yumanity Therapeutics (YMTX) announced that its reverse merger with Proteostasis Therapeutics (PTI) closed on December 22, Piper Sandler analyst Edward Tenthoff reiterated his Overweight rating on Yumanity shares updated his price target to $36 to account for the completion of the merger, completion of a 20:1 reverse stock split and closure of the … The number of analysts covering the stock of PTI is higher than 22.93% of Pharmaceutical Products stocks. MarketBeat just released five new trading ideas, but Proteostasis Therapeutics wasn't one of them. Their average twelve-month price target is $4.67, predicting that the stock has a possible downside of 73.74%. All 25 analysts tracking the company have a ‘buy’ rating on the stock. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. And bought this instead! This price target is based on 5 analysts offering 12 month price targets for Proteostasis Therapeutics in the last 3 months. One share of PTI stock can currently be purchased for approximately $17.77. The stock has traded between $1.03 and $1.08 so far today. Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Baird and H.C. Wainwright & Co. were co-managers. PTI | A complete PTI overview by MarketWatch. Receive a free world-class investing education from MarketBeat. 4 Wall Street analysts have issued ratings and price targets for Proteostasis Therapeutics in the last 12 months. Based on aggregate information from My MarketBeat watchlists, some companies that other Proteostasis Therapeutics investors own include Idera Pharmaceuticals (IDRA), BHP Group (BHP), Sorrento Therapeutics (SRNE), OPKO Health (OPK), Amarin (AMRN), Matinas BioPharma (MTNB), Micron Technology (MU), Rite Aid (RAD), VBI Vaccines (VBIV) and Acasti Pharma (ACST). View our full suite of financial calendars and market data tables, all for free. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Proteostasis Therapeutics has received 58.18% “underperform” votes from our community. He’s now moved $3.8 BILLION in a tiny niche of the tech sector billionaires are flocking to…document.write(''); Sign-up to receive the latest news and ratings for PTI and its competitors with MarketBeat's FREE daily newsletter. Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter. In a report issued on April 24, Brian Abrahams from RBC Capital reiterated a Buy rating on Proteostasis Therapeutics (PTI – Research Report), with a price target of $7.00.The company’s shares closed last Friday at $1.31. The official website for Proteostasis Therapeutics is www.proteostasis.com. Only 16.64% of the stock of Proteostasis Therapeutics is held by institutions. Proteostasis Therapeutics' management team includes the following people: A Powerful Day Trading Strategy that can produce $300 - $500 in just 15 Minutes, Reserve your free virtual seat to an exclusive trading session with legendary trader Tyson Clayton, Start Your Risk-Free Trial Subscription Here, Warren Buffett again encourages investors to bet on America, Biden hails House passage of $1.9T virus bill, now to Senate, Pandemic leaves tribes without US recognition at higher risk, The Latest: U.S. FDA approves J&J single-shot vaccine, Biden team readies wider economic package after virus relief, In oil-rich Iraq, a few women buck norms, take rig site jobs, The Latest: Collins: Reconsider U.S.-Canada border limits, Cronos Stock Pulls Back After Earnings, It Might Be Time To Buy Some, Guardion Health Sciences Stock Needs to Give Investors More Than Survival, Wait For a Better Price Before Placing a Bet On Churchill Downs, 3 Small Cap Dividend Stocks with Growth Prospects, It’s Okay to Take the Over on DraftKings Stock, 7 Undervalued Stocks That Deserve More Attention, 7 Semiconductor Stocks Set to Gain From the Chip Shortage, 7 Great Dividend Stocks to Buy For a Comfortable Retirement, 7 Penny Stocks That Don’t Care About Robinhood, 7 Hotel Stocks Just Waiting For the Vaccine, 7 Stocks to Watch When Student Debt Forgiveness Gets Passed, 7 Healthcare Stocks Delivering Innovation in 2021, 7 Lithium Stocks That Will Power the Electric Vehicle Boom, 7 Electric Vehicle (EV) Stocks That Have Real Juice, 7 Post-Inauguration Stocks to Buy For Under $20, Here's Why We're Watching Proteostasis Therapeutics' (NASDAQ:PTI) Cash Burn Situation, Proteostasis Therapeutics, Inc. 326 E 8th St #105, Sioux Falls, SD 57103 | [email protected] | (844) 978-6257 It has collaboration agreements with Cystic Fibrosis Foundation, Inc. to research, develop, and commercialize products for the treatment of CF, non-classical CF, and other pulmonary diseases in the United States or the European Union; and Genentech, Inc. for licensing the technology and materials relating to therapeutic small molecule modulators.